Axsome Therapeutics (AXSM) Net Cash Flow (2015 - 2026)

Axsome Therapeutics has reported Net Cash Flow for 12 years, with the latest figure at -$17.8 million in Q1 2026.

• Quarterly Net Cash Flow fell 23.43% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 113.74% YoY) and the FY2025 annual result came in at $7.6 million, up 110.7% from the prior year.
• Net Cash Flow slipped to -$17.8 million in Q1 2026 per AXSM's latest filing, from -$2.3 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $190.6 million in Q2 2023 and troughed at -$54.8 million in Q1 2024.
• A 5-year average of $12.9 million and a median of -$11.3 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow jumped 2687.71% in 2023, then sank 219.88% in 2024.
• Over 5 years, Net Cash Flow stood at -$26.7 million in 2022, then decreased by 13.84% to -$30.4 million in 2023, then jumped by 60.53% to -$12.0 million in 2024, then surged by 80.49% to -$2.3 million in 2025, then plunged by 662.16% to -$17.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$17.8 million, -$2.3 million, and $22.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.